Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer

Table 4 Relationship of different clinicopathological characteristics and prognosis

Clinicopathological characteristics	HER2 positive			HER2 negative			χ2	P value
	Median survival time (mo)	1-year survival rate	2-year survival rate	Median survival time (mo)	1-year survival rate	2-year survival rate
Sex
Male	20	74.34%	50.18%	20	83.96%	69.00%	2.2591	0.1328
Female	10	100.00%	50.00%	16.5	74.50%	51.79%	0.0182	0.8927
Age (yr)
≤ 60	23	100.00%	57.14%	20	80.54%	61.81%	0.0104	0.9186
> 60	15	67.55%	49.13%	18	80.62%	64.35%	1.6356	0.2009
Tumor site
Cardiac	19	66.67%	50.00%	15	69.51%	49.15%	0.0494	0.8242
Body	16.5	62.50%	62.50%	14	67.80%	44.07%	0.1561	0.6927
Pylorus	17	85.56%	46.67%	20	87.00%	73.25%	2.3295	0.1269
Lauren classification
Intestinal	17	84.85%	50.91%	27	89.17%	76.53%	2.3604	0.1244
Diffues/mixed	14	67.53%	49.24%	16.5	76.99%	57.24%	0.1907	0.6623
Tumor differentiation
Well-differentiated	18.5	84.42%	50.65%	27.5	96.00%	86.89%	6.2701	0.0123
Poorly-differentiated	14	67.88%	49.49	17	76.56%	56.71%	0.0988	0.7532
TNM classification
I and II stages	18.5	68.57%	57.14%	21.5	93.60%	79.20%	2.9813	0.0842
III and IV stages	17	82.59%	45.88%	16.5	73.32%	54.12%	0.0263	0.8711
T
T1-T	17	66.67%	66.67%	28	100.00%	92.31%	3.4587	0.0629
T3-T4	15	91.30%	46.99%	17	77.47%	58.26%	0.2953	0.5869
N
N0	14	68.57%	51.43%	21	90.46%	74.98%	2.0667	0.1505
N1-N3	18.5	79.19%	49.49%	17	75.73%	57.27%	0.0531	0.8177
M
M0	17	78.67%	54.69%	20	84.41%	66.01%	0.7842	0.3757
M1	11.5	50.00%	0.00%	5	0.00%	0.00%	0.5900	0.4424

HER2: Human epidermal growth factor receptor 2.